Sellas Life Sciences (SLS) Jumps on ASH M&A Speculation

Sellas Life Sciences (NASDAQ: SLS) shares climbed over 3% late Sunday as retail investors speculated that its exhibition booth at the American Society of Hematology annual meeting could signal potential pharmaceutical buyout interest.

### Tape / Session Read Sellas Life Sciences closed Friday at $11.65, rising more than 3% for the session despite a 1% decline for the week. Retail volume on Stocktwits increased alongside neutral sentiment, driven by discussions surrounding the company's 600-square-foot booth presence at the upcoming $ASH+WL conference in New Orleans.

### Clinical and Exhibition Context The $ASH+WL annual meeting scheduled for December 12 to December 15 brings together hematology specialists and major pharmaceutical entities. Sellas is positioned in Hall G alongside large drugmakers including Eli Lilly, AstraZeneca, and Takeda. Clinically, Sellas is advancing galinpepimut-S in a Phase 3 Regal trial for acute myeloid leukemia, which stands at 78 recorded deaths toward its 80-death final analysis threshold as of May 11. A separate Phase 2 study evaluating SLS009 enrolled 80 patients as of August 28, with initial results anticipated in the fourth quarter.

### Money Play If clinical milestones approach their preset event thresholds, watch $SLS+WL because trial progression and conference positioning drive retail sentiment and M&A speculation. For broader healthcare sector rotation and drug pricing policy exposure, watch $LLY+WL as large-cap pharmaceutical valuations react to ongoing clinical catalysts and regulatory developments.